期刊文献+

肌张力障碍治疗中国专家共识 被引量:31

Chinese expert consensus on the treatment of dystonia
原文传递
导出
摘要 肌张力障碍的治疗主要包括支持和康复治疗、口服药物、肉毒毒素注射和手术治疗等,以期达到减少不自主运动、纠正异常姿势、减轻疼痛、改善功能和提高生活质量的治疗目标。本共识写作组参考国际指南和共识,结合中国临床实践现状和专家观点,经充分讨论后形成了相关的共识意见,希望对肌张力障碍的治疗提供指导和参考。 The treatment of dystonia mainly includes rehabilitation,oral medications,botulinum toxin injection and surgical procedure,etc.,in order to achieve the goals of reducing involuntary movements,correcting abnormal postures,reducing pain,improving function and quality of life.This consensus was developed by drawing on the international guidelines and consensus,combined with the clinical experience of Chinese experts after extensive discussions.
作者 万新华 陈海波 张建国 王琳 靳令经 郭毅 无;Wan Xinhua;Chen Haibo;Zhang Jianguo(Chinese Society of Parkinson's Disease and Movement Disorders;Chinese Society of Functional Neurosurgery;The Neurotoxin Branch of Chinese Neuroscience Society;Parkinson's Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association;Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Neurology,Beijing Hospital,Beijing 100730,China;Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)
出处 《中华神经科杂志》 CAS CSCD 北大核心 2020年第11期868-874,共7页 Chinese Journal of Neurology
关键词 肌张力 张力障碍 肉毒毒素类 脑深部电刺激 治疗 共识 Muscle tonus Dystonic disorders Botulinum toxins Deep brain stimulation Treatment Consensus
  • 相关文献

参考文献3

二级参考文献26

  • 1Xin-huaWan,KevinDatVuong,JosephJankovic.CLINICAL APPLICATION OF BOTULINUM TOXIN TYPE B IN MOVEMENT DISORDERS AND AUTONOMIC SYMPTOMS[J].Chinese Medical Sciences Journal,2005,20(1):44-47. 被引量:6
  • 2Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary ( idiopathic ) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. EurJ Neurol, 2006,13: 433-444.
  • 3Klein C, Friedman J, Bressman S, et al. Genetic testing for earlyonset torsion dystonia ( DYT1 ) : introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. Genet Test, 1999, 3:323-328 .
  • 4Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology, 2000, 54: 1746- 1752.
  • 5Robinson R, McCarthy GT, Bandmann O, et al. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry, 1999, 66 : 86-89.
  • 6Valente EM, Edwards MJ, Mir P, et al. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology, 2005, 64: 737-739.
  • 7Meunier S, Lehericy S, Gamero L, et al. Dystonia: lessons from brain mapping . Neuroscientist, 2003, 9: 76-81.
  • 8Jankovic J. Treatment of dystonia. Lancet Neurol, 2006, 5 : 864- 872.
  • 9Berardelli A, Abbruzzese G, Bertolasi L, et al. Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Ital J Neurol Sci, 1997, 18: 261-269.
  • 10Tarsy D, Simon DK. Dystonia. N Engl J Med, 2006,355:818- 829.

共引文献141

同被引文献200

引证文献31

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部